On November 9, the Brain Institute of Rio Grande do Sul signed a contract with the R2IBF group, a company focused on the production and development of high quality radiopharmaceuticals. As of March 2021, all product manufacturing for R2 customers in the states of Rio Grande do Sul and southern Santa Catarina will be the responsibility of InsCer. R2IBF keeps the commercial and logistics area. They are hospitals and clinics that offer PET / CT examination and, therefore, use radiopharmaceuticals.

Inscer and R2IBF's longstanding partnership in research and development of new radiopharmaceuticals will not be affected, on the contrary, it will be strengthened. With this, the whole society wins, and especially the patients who depend on nuclear medicine for earlier and more accurate diagnoses of their illnesses.

Brother Evilázio Teixeira, Rector of PUCRS, was present at the event; Dr. Jaderson Costa da Costa, director of InsCer; José Martins, Chairman of the Board of Directors of the R2IBF Group; Alberto Martins, CEO of the R2IBF Group, Dr. Paulo Togni, IBF's CEO, Roberto Vieira, R2IBF Group's Executive Director and Alexandre Tavares, R2's Executive Director.